2018 American Society of Hematology Annual Meeting*

Hematology 2018 Conference Image
Download All
December 1-4, 2018; San Diego, California
Review slidesets and analyses of key data from the 2018 Hematology meeting.


Capsule Summary Slidesets

Investigational anti-CD33 antibody–drug conjugate with a novel mechanism of action demonstrated preliminary antileukemia activity and tolerability in dose-escalation study.

Released: December 3, 2018

Nearly all patients who received sequential HCVAD with blinatumomab achieved MRD-negative status.

Released: December 4, 2018

Frontline blinatumomab with POMP maintenance was well tolerated with no early deaths in this cohort of patients aged 65 years or older.

Released: December 3, 2018

Early results show addition of blinatumomab to inotuzumab ozogamicin plus mini-HCVD efficacious in older patients with newly diagnosed Ph- ALL.

Released: December 3, 2018

Nonrandomized, observational study suggests reduced event-free survival in patients receiving generic vs branded imatinib.

Released: December 5, 2018

Venetoclax with HMA active and tolerable in hard-to-treat elderly AML patients.

Released: December 5, 2018

Long-term OS benefit was observed in patients with Ph-negative ALL, particularly those who achieved complete MRD response after the first cycle of blinatumomab or while in first CR

Released: December 7, 2018

In patients with newly diagnosed AML with IDH1 or IDH2 mutations, addition of ivosidenib or enasidenib to standard chemotherapy was associated with good tolerability, mutation clearance, and MRD negativity.

Released: December 18, 2018

In patients with R/R FLT3-ITD–mutated AML, single-agent quizartinib significantly prolongs survival compared with salvage chemotherapy with a low incidence of grade 3 QT prolongation.

Released: December 17, 2018

Combination of the FLT3 inhibitor gilteritinib with standard intensive chemotherapy was active and tolerable as first-line AML therapy.

Released: December 5, 2018

Sorafenib maintenance therapy after transplantation significantly reduced the disease relapse rate and improved survival compared with placebo in patients with FLT3-ITD AML.

Released: December 10, 2018
Provided by the Annenberg Center for Health Sciences at Eisenhower.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings